213 related articles for article (PubMed ID: 16817233)
1. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
Espinoza-Fonseca LM; Trujillo-Ferrara JG
Biopolymers; 2006 Nov; 83(4):365-73. PubMed ID: 16817233
[TBL] [Abstract][Full Text] [Related]
2. Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics.
Pantelopulos GA; Mukherjee S; Voelz VA
Proteins; 2015 Sep; 83(9):1665-76. PubMed ID: 26138282
[TBL] [Abstract][Full Text] [Related]
3. Binding induced folding in p53-MDM2 complex.
Chen HF; Luo R
J Am Chem Soc; 2007 Mar; 129(10):2930-7. PubMed ID: 17302414
[TBL] [Abstract][Full Text] [Related]
4. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft.
Showalter SA; Bruschweiler-Li L; Johnson E; Zhang F; Brüschweiler R
J Am Chem Soc; 2008 May; 130(20):6472-8. PubMed ID: 18435534
[TBL] [Abstract][Full Text] [Related]
5. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
[TBL] [Abstract][Full Text] [Related]
6. A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings.
Chen J; Wang J; Zhu W; Li G
J Comput Aided Mol Des; 2013 Nov; 27(11):965-74. PubMed ID: 24264557
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the Free-Energy Landscape of MDM2 Protein-Ligand Interactions by Steered Molecular Dynamics Simulations.
Hu G; Xu S; Wang J
Chem Biol Drug Des; 2015 Dec; 86(6):1351-9. PubMed ID: 26032728
[TBL] [Abstract][Full Text] [Related]
8. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
9. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
10. Comparative Dynamic Features of Apo and Bound MDM2 Protein Reveal the Mechanism of Inhibitor Recognition for Anti-Cancer Activity.
I El Habbash A; El Rashedy A; Soliman MES
Curr Med Chem; 2023; 30(10):1193-1206. PubMed ID: 35702782
[TBL] [Abstract][Full Text] [Related]
11. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.
Dastidar SG; Lane DP; Verma CS
J Am Chem Soc; 2008 Oct; 130(41):13514-5. PubMed ID: 18800837
[TBL] [Abstract][Full Text] [Related]
12. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
13. Direct observations of conformational distributions of intrinsically disordered p53 peptides using UV Raman and explicit solvent simulations.
Xiong K; Zwier MC; Myshakina NS; Burger VM; Asher SA; Chong LT
J Phys Chem A; 2011 Sep; 115(34):9520-7. PubMed ID: 21528875
[TBL] [Abstract][Full Text] [Related]
14. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
[TBL] [Abstract][Full Text] [Related]
15. Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction.
Ciemny MP; Debinski A; Paczkowska M; Kolinski A; Kurcinski M; Kmiecik S
Sci Rep; 2016 Dec; 6():37532. PubMed ID: 27905468
[TBL] [Abstract][Full Text] [Related]
16. Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.
ElSawy KM; Lane DP; Verma CS; Caves LS
J Phys Chem B; 2016 Jan; 120(2):320-8. PubMed ID: 26701330
[TBL] [Abstract][Full Text] [Related]
17. Markov models of the apo-MDM2 lid region reveal diffuse yet two-state binding dynamics and receptor poses for computational docking.
Mukherjee S; Pantelopulos GA; Voelz VA
Sci Rep; 2016 Aug; 6():31631. PubMed ID: 27538695
[TBL] [Abstract][Full Text] [Related]
18. A spatiotemporal characterization of the effect of p53 phosphorylation on its interaction with MDM2.
ElSawy KM; Sim A; Lane DP; Verma CS; Caves LS
Cell Cycle; 2015; 14(2):179-88. PubMed ID: 25584963
[TBL] [Abstract][Full Text] [Related]
19. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
20. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
